NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President and Chief Executive Officer, Sandip Kapadia, Chief Financial Officer, and Gail Cawkwell, M.D., Ph.D., SVP, Medical Affairs, Safety and Pharmacovigilance of Intercept, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Tuesday, December 1, 2020 from 3:30 – 3:55 p.m. ET.
A live webcast of the event will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. An audio archive of the webcast will also be available on Intercept’s website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
Contact
For more information about Intercept, please contact:
Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
(Now your health can be as cutting-edge as your wallet in 2025.) PORTLAND, Ore., Jan.…
AUSTIN, Texas, Jan. 1, 2025 /PRNewswire/ -- re:3D, Inc. is pleased to announce the winner…
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize…
Provides financial flexibility by reducing near-term debt maturities, deferring principal redemption payment, and reducing near-term…
Innovative Solutions Transform Treatment for Burn Victims, Chronic Wounds, and Scar ReductionCHICAGO, Dec. 31, 2024…
TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or…